This content is machine translated Results of the FOREST HCM study Symptomatic obstructive hypertrophic cardiomyopathy Myosin inhibition is considered a key therapeutic approach in the treatment of obstructive hypertrophic cardiomyopathy (oHCM). In addition to mavacamten, aficamten is now being clinically investigated as a potentially short-acting,...…
